The protein landscape of chronic lymphocytic leukemia

Fabienne Meier‐Abt(University of Zurich), Thorsten Zenz(Universität Ulm)

Blood

July 1, 2021

10.1182/blood.2020009741

Cited by 33

Related Papers

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

|Nature Communications|2016|346

p53-dependent non-coding RNA networks in chronic lymphocytic leukemia

|Leukemia|2015|170

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

|Nature Communications|2022|42

TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma

|Blood|2018|35

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

|Blood|2025|3